92 related articles for article (PubMed ID: 8917423)
1. Biochemical characterization of cisplatin-resistance in MKN-45 human stomach adenocarcinoma cell line.
Hong WS; Son YS
Anticancer Res; 1996; 16(5A):3031-6. PubMed ID: 8917423
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin.
Hong WS; Jung HY; Yang SK; Kim HR; Min YI
Anticancer Res; 1997; 17(5A):3613-6. PubMed ID: 9413212
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
Moritaka T; Kiura K; Ueoka H; Tabata M; Segawa Y; Shibayama T; Takigawa N; Ohnoshi T; Harada M
Anticancer Res; 1998; 18(2A):927-33. PubMed ID: 9615743
[TBL] [Abstract][Full Text] [Related]
4. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
Hill BT; Shellard SA; Hosking LK; Dempke WC; Fichtinger-Schepman AM; Tone T; Scanlon KJ; Whelan RD
Cancer Res; 1992 Jun; 52(11):3110-8. PubMed ID: 1591724
[TBL] [Abstract][Full Text] [Related]
7. Characterization and resistance mechanisms of cisplatin-resistant human hepatocellular carcinoma cell line.
Yang JX; Luo Y; Qiu HM; Tang WX
Saudi Med J; 2009 Jan; 30(1):35-40. PubMed ID: 19139770
[TBL] [Abstract][Full Text] [Related]
8. A novel telomere elongation in an adriamycin-resistant stomach cancer cell line with decreased telomerase activity.
Kim JH; Lee GE; Kim JC; Lee JH; Chung IK
Mol Cells; 2002 Apr; 13(2):228-36. PubMed ID: 12018844
[TBL] [Abstract][Full Text] [Related]
9. Chemoresistance to doxorubicin and cisplatin in a murine cell line. Analysis of P-glycoprotein, topoisomerase II activity, glutathione and related enzymes.
Mestdagh N; Pommery N; Saucier JM; Hecquet B; Fournier C; Slomianny C; Teissier E; Hénichart JP
Anticancer Res; 1994; 14(3A):869-74. PubMed ID: 7915509
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
Teicher BA; Holden SA; Kelley MJ; Shea TC; Cucchi CA; Rosowsky A; Henner WD; Frei E
Cancer Res; 1987 Jan; 47(2):388-93. PubMed ID: 3539321
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP.
Zhan M; Liu X
Chin Med J (Engl); 1999 Apr; 112(4):336-9. PubMed ID: 11593534
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of an acquired cisplatin-resistant subline in a human osteosarcoma cell line.
Asada N; Tsuchiya H; Ueda Y; Tomita K
Anticancer Res; 1998; 18(3A):1765-8. PubMed ID: 9673402
[TBL] [Abstract][Full Text] [Related]
13. Analysis of cellular sensitization with cisplatin-induced apoptosis by glucose-starved stress in cisplatin-sensitive and -resistant A431 cell line.
Mese H; Sasaki A; Nakayama S; Yokoyama S; Sawada S; Ishikawa T; Matsumura T
Anticancer Res; 2001; 21(2A):1029-33. PubMed ID: 11396136
[TBL] [Abstract][Full Text] [Related]
14. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
[TBL] [Abstract][Full Text] [Related]
15. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil.
Chen CC; Chen LT; Tsou TC; Pan WY; Kuo CC; Liu JF; Yeh SC; Tsai FY; Hsieh HP; Chang JY
Br J Cancer; 2007 Aug; 97(3):334-44. PubMed ID: 17609664
[TBL] [Abstract][Full Text] [Related]
16. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
Yan XD; Li M; Yuan Y; Mao N; Pan LY
Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells.
Goto S; Yoshida K; Morikawa T; Urata Y; Suzuki K; Kondo T
Cancer Res; 1995 Oct; 55(19):4297-301. PubMed ID: 7671239
[TBL] [Abstract][Full Text] [Related]
18. cis-diamminedichloroplatinum(ii) resistance in vitro and in vivo in human embryonal carcinoma cells.
Timmer-Bosscha H; Timmer A; Meijer C; de Vries EG; de Jong B; Oosterhuis JW; Mulder NH
Cancer Res; 1993 Dec; 53(23):5707-13. PubMed ID: 8242627
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
20. [Establishment of human ovarian cancer cisplatin resistant cell line COC1/DDP and its mechanism of resistance].
Zhou Y; Chen H; Yang Q
Zhonghua Yi Xue Za Zhi; 1996 Sep; 76(9):680-3. PubMed ID: 9275551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]